The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors

被引:2
|
作者
Pavel, Marianne [1 ]
Dromain, Clarisse [2 ]
Ronot, Maxime [3 ]
Schaefer, Niklaus [2 ]
Mandair, Dalvinder [4 ]
Gueguen, Delphine [5 ]
Elvira, David [5 ]
Jegou, Simon [6 ]
Balazard, Felix [6 ]
Dehaene, Olivier [6 ]
Schutte, Kathryn [6 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
[2] Lausanne Univ Hosp, Lausanne, Switzerland
[3] Beaujon Hosp, Clichy, France
[4] Royal Free Hosp, London, England
[5] Ipsen, Boulogne Billancourt, France
[6] Owkin, Paris, France
关键词
artificial intelligence; deep learning; neuroendocrine tumors; progression-free survival; RECIST; CONSENSUS GUIDELINES; CLINICAL UTILITY; CHROMOGRANIN-A; DIAGNOSIS; METASTASES; MANAGEMENT; RADIOMICS; RECIST;
D O I
10.2217/fon-2022-1136
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plain language summary - The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumorsNeuroendocrine tumors (NET) are slow-growing cancers. How well cancers respond to treatment is usually measured using 'Response Evaluation Criteria in Solid Tumors (RECIST)', which is based on measuring the size of tumors. RECIST is not well suited for assessing NETs as these tumors often grow slowly and rarely shrink significantly, so it is difficult to tell whether a treatment has any effect. A better way of measuring how well NETs are responding to treatment is needed, to ensure that patients receive the right treatment as early as possible.The RAISE project aimed to use a type of artificial intelligence (AI) called 'deep learning' to examine images of NETs, taken from patients in a clinical trial of treatment with lanreotide, to help predict how they might respond to treatment. These images were analyzed by the deep learning AI to see if there are any features of tumors, other than shape or size, that may help to predict response to treatment.The project showed that this technology can detect features in images of NETs, other than the shape and size of tumors, that are useful for predicting how well a treatment might work for an individual patient. However, this technology could not improve prediction of how well a treatment would work at an earlier stage compared with other currently used indicators.Overall, further research and work is needed to improve this technology. However, these results show that deep learning may have the potential to improve prediction of treatment response in patients with NETs. Aim: The RAISE project assessed whether deep learning could improve early progression-free survival (PFS) prediction in patients with neuroendocrine tumors. Patients & methods: Deep learning models extracted features from CT scans from patients in CLARINET (NCT00353496) (n = 138/204). A Cox model assessed PFS prediction when combining deep learning with the sum of longest diameter ratio (SLDr) and logarithmically transformed CgA concentration (logCgA), versus SLDr and logCgA alone. Results: Deep learning models extracted features other than lesion shape to predict PFS at week 72. No increase in performance was achieved with deep learning versus SLDr and logCgA models alone. Conclusion: Deep learning models extracted relevant features to predict PFS, but did not improve early prediction based on SLDr and logCgA.
引用
收藏
页码:2185 / 2199
页数:15
相关论文
共 50 条
  • [21] Using integrated radiomic and pathomic-based models to predict progression-free survival in early-stage lung adenocarcinoma
    Zhang, Tengyue
    Yadav, Anil
    Ding, Ruiwen
    Johnson, Sean
    Aberle, Denise
    Prosper, Ashley
    Rodriguez, Erika
    Araujo Lemos da Silva, Ana Cristina
    Hsu, William
    DIGITAL AND COMPUTATIONAL PATHOLOGY, MEDICAL IMAGING 2024, 2024, 12933
  • [22] Association of Computed Tomography Radiomics Signature with Progression-free Survival in Neuroblastoma Patients
    Wang, H.
    Li, T.
    Xie, M.
    Si, J.
    Qin, J.
    Yang, Y.
    Zhang, L.
    Ding, H.
    Chen, X.
    He, L.
    CLINICAL ONCOLOGY, 2023, 35 (11) : e639 - e647
  • [23] Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
    C K Lee
    R J Simes
    C Brown
    S Lord
    U Wagner
    M Plante
    I Vergote
    C Pisano
    G Parma
    A Burges
    H Bourgeois
    T Högberg
    J Bentley
    L Angleitner-Boubenizek
    A Ferrero
    B Richter
    H Hirte
    V Gebski
    J Pfisterer
    E Pujade-Lauraine
    M Friedlander
    British Journal of Cancer, 2011, 105 : 1144 - 1150
  • [24] Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
    Lee, C. K.
    Simes, R. J.
    Brown, C.
    Lord, S.
    Wagner, U.
    Plante, M.
    Vergote, I.
    Pisano, C.
    Parma, G.
    Burges, A.
    Bourgeois, H.
    Hogberg, T.
    Bentley, J.
    Angleitner-Boubenizek, L.
    Ferrero, A.
    Richter, B.
    Hirte, H.
    Gebski, V.
    Pfisterer, J.
    Pujade-Lauraine, E.
    Friedlander, M.
    BRITISH JOURNAL OF CANCER, 2011, 105 (08) : 1144 - 1150
  • [25] Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival
    Chen, James X.
    Rose, Steven
    White, Sarah B.
    El-Haddad, Ghassan
    Fidelman, Nicholas
    Yarmohammadi, Hooman
    Hwang, Winifred
    Sze, Daniel Y.
    Kothary, Nishita
    Stashek, Kristen
    Wileyto, E. Paul
    Salem, Riad
    Metz, David C.
    Soulen, Michael C.
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2017, 40 (01) : 69 - 80
  • [26] A Nomogram for Predicting Progression-free Survival in Patients with Endometrial Cancer
    Wang, Z.
    Zhao, Z.
    Li, W.
    Bao, X.
    Liu, T.
    Yang, X.
    CLINICAL ONCOLOGY, 2023, 35 (09) : e516 - e527
  • [27] Novel Prognostic Nomogram to Predict Progression-Free Survival of Patients with Hepatocellular Carcinoma After Transarterial Chemoembolization
    Xi, Dong
    Xu, Mengying
    Han, Meiwen
    Guan, Qianting
    Guo, Qinghao
    Yan, Fangfei
    Yao, Junxia
    Ning, Qin
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 909 - 920
  • [28] Development and validation of a nomogram based on stromal score to predict progression-free survival of patients with papillary thyroid carcinoma
    Tang, Jiajia
    Jiang, Shitao
    Gao, Qiong
    Xi, Xuehua
    Gao, Luying
    Zhao, Ruina
    Lai, Xingjian
    Zhang, Bo
    Jiang, Yuxin
    CANCER MEDICINE, 2021, 10 (16): : 5488 - 5498
  • [29] Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin
    Sommer, Wieland H.
    Ceelen, Felix
    Garcia-Albeniz, Xabier
    Paprottka, Philipp M.
    Auernhammer, Christoph J.
    Armbruster, Marco
    Nikolaou, Konstantin
    Haug, Alexander R.
    Reiser, Maximilian F.
    Theisen, Daniel
    EUROPEAN RADIOLOGY, 2013, 23 (11) : 3094 - 3103
  • [30] Absolute Counts of Peripheral Lymphocyte Subsets Correlate with the Progression-Free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumour Patients
    Gong, Yitao
    Fan, Zhiyao
    Luo, Guopei
    Huang, Qiuyi
    Qian, Yunzhen
    Cheng, He
    Jin, Kaizhou
    Ni, Quanxing
    Yu, Xianjun
    Liu, Chen
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6727 - 6737